UK Markets open in 57 mins
NIKKEI 225
26,650.92 +103.87 (+0.39%) HANG SENG
20,449.26 +499.05 (+2.50%) CRUDE OIL
113.92 -0.28 (-0.25%) GOLD FUTURES
1,827.00 +13.00 (+0.72%) DOW
32,223.42 +26.76 (+0.08%) BTC-GBP
24,620.29 +36.96 (+0.15%)
Zymeworks Inc. (ZYME)
NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 5.55 |
| Open | 5.55 |
| Bid | 0.00 x 1200 |
| Ask | 0.00 x 1800 |
| Day's range | 5.31 - 5.64 |
| 52-week range | 4.56 - 39.41 |
| Volume | |
| Avg. volume | 1,716,325 |
| Market cap | 248.598M |
| Beta (5Y monthly) | 1.08 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.45 |
| Earnings date | 22 Feb 2022 - 28 Feb 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 26.09 |
- Zacks
Zymeworks Inc. (ZYME) Reports Q1 Loss, Lags Revenue Estimates
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -22.68% and 49.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Zymeworks Provides Corporate Update and Reports First Quarter 2022 Financial Results
VANCOUVER, British Columbia, May 04, 2022--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the first quarter ended March 31, 2022.
- Business Wire
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia & SEATTLE, May 02, 2022--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in an upcoming investor conference:
© 2022 Yahoo. All rights reserved.
